Bedtime-to-Morning Glucose Differential (BeAM)
The bedtime-to-morning glucose differential (BeAM) is the difference between glucose levels measured at bedtime and the following morning's fasting glucose, with a value ≥50 mg/dL (≥2.8 mmol/L) serving as a critical clinical indicator of insulin overbasalization and inadequate postprandial glucose control in patients with type 2 diabetes on basal insulin therapy 1.
Clinical Definition and Significance
The BeAM value represents a simple calculation: bedtime glucose minus pre-breakfast (morning fasting) glucose. When this differential reaches or exceeds 50 mg/dL, it signals that:
- Basal insulin is being used at higher than clinically necessary doses, masking insufficient mealtime insulin coverage 1
- Postprandial hyperglycemia is inadequately controlled throughout the day, despite acceptable fasting glucose levels 2, 3
- The patient requires intensification of therapy beyond basal insulin alone 4, 5
Why This Metric Matters
A high BeAM value (≥50 mg/dL) indicates that glucose rises significantly during the day from meals but then drops overnight due to excessive basal insulin suppressing hepatic glucose production. This pattern reveals a fundamental mismatch between the patient's insulin regimen and their physiologic needs 1.
Key clinical signals that should prompt BeAM evaluation include:
- Basal insulin dose >0.5 units/kg 2, 3
- High preprandial-to-postprandial glucose differential 1
- Hypoglycemia (aware or unaware) 2, 1, 3
- High glucose variability 2, 3
Clinical Action Based on BeAM Values
When BeAM ≥50 mg/dL:
Reevaluate the glucose-lowering treatment plan immediately to better address postprandial hyperglycemia rather than continuing to increase basal insulin 1. The most recent 2025 ADA guidelines emphasize this threshold consistently across multiple years of recommendations.
Treatment intensification options include:
- Add a GLP-1 receptor agonist or dual GIP/GLP-1 RA (preferred first-line approach to minimize hypoglycemia and weight gain risk) 1
- Add prandial insulin starting with a single dose at the largest meal (4 units or 10% of basal insulin dose) 1
- Consider reducing basal insulin while adding mealtime coverage 1
When BeAM <50 mg/dL:
Research demonstrates that achieving a BeAM <55 mg/dL is associated with:
- Improved overall glycemic control 4
- Lower risk of hypoglycemia 4
- Greater proportion of patients achieving glycemic targets without hypoglycemia or weight gain 4
Evidence Strength and Consistency
The BeAM threshold of ≥50 mg/dL appears consistently across multiple years of ADA Standards of Care (2022,2023,2024,2025) 2, 1, 3, 1, 6, making it a well-established clinical marker. The 2025 guidelines provide the most recent and explicit definition, specifying the exact threshold of ≥50 mg/dL (≥2.8 mmol/L) 1.
Supporting research confirms that patients with high BeAM values benefit from therapy intensification, with significant reductions in HbA1c and postprandial glucose when prandial insulin or GLP-1 RAs are added 4, 5.
Practical Implementation
To calculate BeAM:
- Measure glucose at bedtime (before sleep)
- Measure fasting glucose the following morning (pre-breakfast)
- Subtract morning value from bedtime value
- If the result is ≥50 mg/dL, overbasalization is likely present
Common pitfall: Continuing to titrate basal insulin upward when BeAM is elevated will worsen the problem by increasing hypoglycemia risk without adequately addressing postprandial hyperglycemia 1.